R&D Planning & Evidence Exploration
when to generate it, and how it will be used to support downstream market access, reimbursement, policy and commercial outcomes.
Early decisions have long-term consequences
Choices made at this stage can either enable or constrain future PBAC, MSAC, Prescribed List and policy funding pathways.
Pulse Economics works with pharmaceutical, biotech, medtech and diagnostics organisations to design forward-looking R&D and evidence strategies.
Our advice is grounded in first-hand PBAC and MSAC evaluation experience, giving us a clear view of how early evidence choices are later interrogated, stress-tested and challenged.
We help clients move beyond:
“What evidence will decision-makers ultimately need?”
R&D planning & evidence support in practice
HTA-aligned evidence gap assessments
Structured mapping of your current evidence base against what PBAC and MSAC will require at submission.
Clinical development pathways & endpoints
Strategic advice ensuring your trial design generates endpoints that will withstand HTA scrutiny.
Early health economic framework development
Establishing value frameworks early before clinical development locks assumptions.
Evidence exploration & comparator positioning
Rigorous literature review to inform comparator selection and clinical context.
Burden of disease & outcomes scoping
Epidemiological assessments quantifying disease prevalence and socioeconomic impact.
Real-world evidence & utility studies
Assessments leveraging real-world data alongside utility studies quantifying quality of life impact.
Ready to accelerate your evidence journey?
Every successful reimbursement outcome begins with evidence planned with the end decision in mind.
Connect With An Access Strategist →